"Fatty Liver" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Descriptor ID |
D005234
|
| MeSH Number(s) |
C06.552.241
|
| Concept/Terms |
Steatohepatitis- Steatohepatitis
- Steatohepatitides
- Steatosis of Liver
- Visceral Steatosis
- Steatoses, Visceral
- Steatosis, Visceral
- Visceral Steatoses
- Liver Steatosis
- Liver Steatoses
- Steatoses, Liver
- Steatosis, Liver
|
Below are MeSH descriptors whose meaning is more general than "Fatty Liver".
Below are MeSH descriptors whose meaning is more specific than "Fatty Liver".
This graph shows the total number of publications written about "Fatty Liver" by people in this website by year, and whether "Fatty Liver" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 4 | 0 | 4 |
| 2007 | 3 | 0 | 3 |
| 2008 | 3 | 1 | 4 |
| 2009 | 8 | 2 | 10 |
| 2010 | 3 | 5 | 8 |
| 2011 | 12 | 4 | 16 |
| 2012 | 8 | 7 | 15 |
| 2013 | 11 | 4 | 15 |
| 2014 | 4 | 1 | 5 |
| 2015 | 2 | 1 | 3 |
| 2016 | 3 | 4 | 7 |
| 2017 | 3 | 3 | 6 |
| 2018 | 6 | 3 | 9 |
| 2019 | 4 | 0 | 4 |
| 2020 | 3 | 1 | 4 |
| 2021 | 4 | 1 | 5 |
| 2023 | 2 | 1 | 3 |
| 2024 | 6 | 10 | 16 |
| 2025 | 10 | 4 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fatty Liver" by people in Profiles.
-
Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States. J Med Econ. 2025 Dec; 28(1):1370-1387.
-
Inter- and intra-observer agreement in ultrasound diagnosis of steatotic liver disease: implications for screening in resource-limited settings. Sci Rep. 2025 Aug 14; 15(1):29819.
-
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025 Jul 01; 48(7):1057-1082.
-
A murine model of gestational diabetes reveals MASLD risk and alterations in markers of hepatic mitochondrial metabolism. Front Endocrinol (Lausanne). 2025; 16:1498764.
-
FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression. Cell Metab. 2025 Jul 01; 37(7):1547-1567.e6.
-
Prevalence of fibrosis in hepatic explants and biopsies from individuals with urea cycle disorders. Mol Genet Metab. 2025 Aug; 145(4):109175.
-
Circulating fibroblast growth factor 21 and growth differentiation factor 15 are associated with severity of hepatic steatosis in people with HIV. HIV Med. 2025 Sep; 26(9):1457-1462.
-
Liver Transplantation and Metabolic Dysfunction Associated Steatotic Liver Disease Is Associated with Markers of Metabolic Risk and Inflammation. Dig Dis Sci. 2025 Jun; 70(6):2147-2155.
-
Association of High-Sensitivity Troponins in Metabolic Dysfunction-Associated Steatotic Liver Disease With All-Cause and Cause-Specific Mortality. Aliment Pharmacol Ther. 2025 Jun; 61(11):1785-1793.
-
Current Burden of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease Among US Adults, 2017-2023. Aliment Pharmacol Ther. 2025 Mar; 61(5):891-894.